In vitro efficacy of the combination of ciprofloxacin and cefotaxime against nalidixic acid-resistant Salmonella enterica serotype Typhi

• Published in: International journal of antimicrobial agents Vol. 36; no. 2; pp. 155 - 158
• Main Authors: Kim, Dong-Min, Neupane, Ganesh Prasad, Jang, Sook Jin, Kim, Sung Hun, Lee, Bok Kwon
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier B.V 01.08.2010; Elsevier
• Subjects: Anti-Infective Agents - pharmacology; Antibiotics; Antibiotics. Antiinfectious agents. Antiparasitic agents; Azithromycin; Bacterial diseases; Bacterial diseases of the digestive system and abdomen; Biological and medical sciences; Cefotaxime; Cefotaxime - pharmacology; Ciprofloxacin; Ciprofloxacin - pharmacology; Drug Resistance, Bacterial; Drug Synergism; Human bacterial diseases; Humans; Infectious Disease; Infectious diseases; Medical sciences; Microbial Sensitivity Tests; Nalidixic Acid - pharmacology; Pharmacology. Drug treatments; Salmonella enterica; Salmonella Typhi; Salmonella typhi - drug effects; Typhoid fever; Typhoid Fever - microbiology; Typhoid fever; Cefotaxime; Ciprofloxacin; Salmonella Typhi; Azithromycin; Salmonella typhi; Fluoroquinolone derivatives; Bacteria; Salmonellosis; Naphtyridine derivatives; Protein synthesis inhibitor; Serotype; Quinolone derivatives; Enterobacteriaceae; Typing; β-Lactams; Treatment efficiency; Typhoid; Macrolide; In vitro; Infection; Resistance; Cephalosporin derivatives; Antibiotic; Nalidixic acid; Bacteriosis; Digestive diseases; Antibacterial agent

Abstract Typhoid fever is a systemic intracellular infection caused by Salmonella enterica serotype Typhi. The emergence and spread of nalidixic acid-resistant S. Typhi (NARST) is challenging for clinicians in many countries owing to the lack of suitable treatment options. The aim of this study was...